Longitudinal serologic and viral testing post–SARS-CoV-2 infection and post-receipt of mRNA COVID-19 vaccine in a nursing home cohort—Georgia, October 2020‒April 2021
Antibody titer
DOI:
10.1371/journal.pone.0275718
Publication Date:
2022-10-27T13:28:27Z
AUTHORS (26)
ABSTRACT
There are limited data describing SARS-CoV-2-specific immune responses and their durability following infection vaccination in nursing home residents. We conducted a prospective longitudinal evaluation of 11 consenting SARS-CoV-2-positive residents to evaluate the quantitative titers binding antibodies detected after SARS-CoV-2 subsequent COVID-19 vaccination. The included nine visits over 150 days from October 25, 2020, through April 1, 2021. Visits questionnaire administration, blood collection for serology, paired anterior nasal specimen testing by BinaxNOW™ Ag Card (BinaxNOW), reverse transcription polymerase chain reaction (RT-PCR), viral culture. evaluated post-infection post-vaccination (beginning first dose primary series). median age among participants was 74 years; one participant immunocompromised. Of 10 with serology results, 9 (90%) had detectable Pan-Ig, IgG, IgA antibodies, 8 (80%) IgM antibodies. At antibody detection post-infection, two-thirds (6/9, 67%) were RT-PCR-positive, but none culture- positive. Ten received vaccination; all final observation ≤90 post-first dose. Post-vaccination geometric means IgG 10-200-fold higher than post-infection. Nursing this cohort mounted robust post-vaccination. augmented potential indicators enhanced protection that may confer on previously infected
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (43)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....